Slovakia plans to keeping using AstraZeneca despite pause


Slovakia's Prime Minister Eduard Heger receives his first AstraZeneca COVID-19 vaccination at the National Soccer Stadium in Bratislava, Slovakia, Saturday, May 1, 2021. The AstraZeneca coronavirus vaccine should remain part of Slovakia’s vaccination program the country’s Health Minister said on Wednesday, May 12. Slovakia on Tuesday halted use of the two-shot AstraZeneca vaccine after Slovakia’s State Institute for Drug Control concluded last week that the death of a 47-year-old woman who received the AstraZeneca was “likely” linked to the vaccine. (Jakub Kotian/TASR via AP)

BRATISLAVA, Slovakia (AP) — Slovakia's health minister says he plans to keep AstraZeneca in the country's vaccine arsenal, speaking a day after the country suspended use of the shots after a recipient died.

Slovakia on Tuesday halted use of the two-shot AstraZeneca vaccine after its State Institute for Drug Control concluded last week that the death of a 47-year-old woman who received the AstraZeneca was "likely” linked to the vaccine.

AstraZeneca is still being administered, however, to those who have already gotten the first dose and are awaiting a second shot. It's currently being given to people between the ages of 18 and 44.

Health Minister Vladimir Lengvarsky said the cause of woman’s death was still under investigation. He said another, and the main reason, for the suspension was that Slovakia does not have enough AstraZeneca shots to continue their administration.

Slovakia, like other members of the European Union, have seen a drop in deliveries from the company.

“We still count on AstraZeneca in our vaccination plan,” Lengvarsky said.

Millions of doses of AstraZeneca have been safely administered in Europe, but concerns linger over a rare type of blood clot seen in an extremely small number of recipients.

Denmark and Norway, countries which are very cautious with all vaccines, suspended their use of AstraZeneca shots in March amid news of the rare blood clots.

Lengvarsky said his ministry was working to allow people to have a free choice beginning in June among the available vaccines, “including the unregistered ones.”

Slovakia has 200,000 doses of Russia-made Sputnik V vaccine available but has not allowed its use yet. Lengvarsky said use of the Russian shots might possibly also start in June. He still has to approve Sputnik V's use.

Slovakia has been administering Pfizer, Moderna and AstraZeneca, and is expected to have Johnson & Johnson soon.


It would be only the second European Union nation after Hungary to use Sputnik V, which has not been authorized by the European Medicines Agency.

A secret deal for Slovakia to purchase 2 million Sputnik V shots orchestrated by then-Prime Minister Igor Matovic triggered a political crisis in March that resulted in the Slovak government’s collapse.

___

Follow AP’s pandemic coverage at:

https://apnews.com/hub/coronavirus-pandemic

https://apnews.com/hub/coronavirus-vaccine

https://apnews.com/UnderstandingtheOutbreak

Should you invest $1,000 in Johnson & Johnson right now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.9351 of 5 stars
$146.14-0.5%3.39%9.11Hold$175.86
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Search Headlines: